1. Luye Pharma Reports Submission of NDA to the US FDA for LY03005 Published: Dec 26, 2019 | Tags: FDA, Luye Pharma, LY03005, NDA, reports, Submission, US 2. Immunomedics Reports […]readmore
Tags : Luye Pharma
Shots: The application is based on the agreement reached with the FDA under End-Of-Phase 2-CMC (EOP2-CMC) & PNDA meeting, marking the second NDA submission to the US FDA in CNS […]readmore
Shots: AstraZeneca to get exclusive promotion rights in China including Taiwan, Hong Kong, Singapore, Malaysia for Luye’s Xuezhikang capsules. Luye Pharma will retain its IPR, commercialization rights, asset rights & […]readmore